DUBLIN, Ireland -- The Cerus (NASDAQ:CERS) Corporate Conference Call took place on 13-Feb-06 11:00am ET.

Co. reported that it gained worldwide commercial rights for the INTERCEPT Blood System for platelets and plasma from Baxter. Together with the rights granted in Feb. 2005, CERS now holds the exclusive right to the INTERCEPT Blood System for all three commonly transfused components (platelets, plasma, and red blood cells).

More information on this Conference Call can be obtained from Research and Markets at http://www.researchandmarkets.com/transcripts/80155

This document provides verbatim text of the conference call.